Skip to main
SER

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics is a promising biotech company with a strong pipeline of drug candidates using their POZ platform technology, particularly in the treatment of Parkinson's disease and Tardive Dyskinesia. The company's upcoming data for SER-252 will be a significant catalyst for their success, with potential for partnerships and revenue from their Grant revenue segment. While there are risks associated with biotech companies, analysts have a positive outlook for Serina Therapeutics, with a projected price target of $40.

Bears say

Serina Therapeutics is facing significant risks and challenges as a clinical-stage biotechnology company, which may negatively impact its stock. These include the potential for unexpected safety signals in upcoming clinical trials for its main product candidate, SER-252, as well as competition from other drug developers and ongoing research into disease-modifying treatments for neurological diseases such as Parkinson's. In addition, the company's focus on its POZ platform and its potential partnerships may divert attention and resources away from its key internal programs. Furthermore, there is a risk of potential commercial challenges, such as pricing and reimbursement coverage, if the company's products are approved for market.

SER has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 1 analysts, SER has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.